Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 14/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP2 | P12104 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31357337 | 1.00 | KRAS (0.50) | KRASFABP4MCL1FABP3FABP2 | |
| SCHEMBL20905233 | 0.81 | OXER1 (0.54) | KRASFGFR1FGFR4HTR2AHTR2C | |
| SCHEMBL20905232 | 0.81 | TFPI2 (0.47) | KRASFABP4HTR2AHTR2C | |
| SCHEMBL4379598 | 0.80 | MCL1 (0.47) | KRASFABP4MCL1FABP3FABP2 | |
| SCHEMBL20905230 | 0.78 | AKR1C3 (0.38) | KRASMCL1 | |
| SCHEMBL5785852 | 0.78 | HTR2A (0.44) | KRASFABP4MCL1FABP3FABP2 | |
| SCHEMBL12749675 | 0.78 | NOTUM (0.58) | FABP4MCL1FABP3FABP2FABP5 | |
| SCHEMBL31607288 | 0.78 | NOTUM (0.58) | FABP4MCL1FABP3FABP2FABP5 | |
| SCHEMBL20905231 | 0.77 | KRAS (0.53) | KRAS | |
| SCHEMBL21401774 | 0.77 | TYR (0.37) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-20210284658-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | YUNGJIN PHARM. CO., LTD. (KR) | 2021-09-16 | — | — | US | disclosed |
| EP-3853225-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Yungjin Pharm. Co., Ltd. (KR) | 2021-07-28 | — | — | EP | disclosed |
| CN-112739695-A | Novel thiazole derivative and pharmaceutically acceptable salt thereof | 永进药品工业株式会社 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020060112-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | YUNGJIN PHARM. CO., LTD. (KR) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284658-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CDKL1, CDKL3, CDKL2 | KRAS 952/4885FABP4 4374/4885MCL1 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.